VAC2VAC- Contribution of the Paul-Ehrlich-Institut
VAC2VAC is a wide-ranging collaborative research project funded by IMI2 which aims to develop and validate quality testing approaches for both human and veterinary vaccines using non-animal methods. The Paul-Ehrlich-Institut is a partner in this project.
High yield at high selectivity – lentiviral vectors with Nipah envelope proteins developed
To transfer genes exclusively into the patient's therapy relevant cells is in the focus of current research approaches in gene therapy. Researchers of the Paul-Ehrlich-Institut have succeeded in modifying envelope proteins of Nipah virus (NiV) and to combine them with lentiviruses in such a way that they can now be used for a highly selective and efficient gene transfer to selected cells.
Important intrinsic factor for the defence against hepatitis B viruses identified – consequences for treatment?
Around 350 million people are chronically infected with the hepatitis B virus world-wide. This is related to a markedly increased risk of liver cancer and liver cirrhosis. Researchers of the Paul-Ehrlich-Institut have discovered an intrinsic cellular factor, SAMHD1, which is upregulated by interferons and inhibits the hepatitis B infection.